Sharing from Twitter
#NotJustFatigue: "Big win in the Senate! After more than a year of advocating for federal research funding, Congress has officially recognized the ME/CFS Research Roadmap—and is now directing NIH to create a detailed implementation plan. This is a major step forward in the fight for treatments, diagnostics, and answers. The Senate language comes straight from our advocacy and
@MEActNet, and shows that your voice is being heard. The House is expected to release its own version in the coming months before the two chambers reconcile later this year. We’ll be fighting to keep this language intact."
"The Senate report also calls for expanded research through the RECOVER Initiative and ARPA-H, specifically naming ME/CFS as a priority."
Here is the FY26 Appropriations
Senate LHHS report, if you search Long COVID or ME/CFS in it.
Source: U.S. Senate / Twitter/X / Not Just Fatigue
Date: August 1, 2025
URL:
Ref: Convert from jpg to txt,
https://document.online-convert.com/convert-to-txt
Big win in the Senate!
After more than a year of advocating for federal research funding,
Congress has officially recognized the ME/CFS Research Roadmap — and is
now directing NIH to create a detailed implementation plan. This is a
major step forward in the fight for treatments, diagnostics, and
answers. The Senate language comes straight from our advocacy and
MEActNet, and shows that your voice is being heard.
The Senate report also calls for expanded research through the RECOVER
Initiative and ARPA-H, specifically naming ME/CFS as a priority.
The House is expected to release its own version in the coming months
before the two chambers reconcile later this year. We'll be fighting to
keep this language intact.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
https://pbs.twimg.com/media/GxOSMnAXkAAdGRD?format=jpg&name=small
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome [ME/CFS] Research
Roadmap.
The Committee recognizes the urgent need to advance research for ME/CFS,
especially given its overlap with Long COVID and relevance across
multiple ICs and commends NIH for approving the ME/CFS Research Roadmap.
The Committee encourages NIH to implement the oadmap's recommendations,
including advancing biomarker discovery, diagnostic tool development,
and clinical trials. NIH is further directed to provide a detailed
implementation plan to the Committee within 180 days of enactment.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
https://pbs.twimg.com/media/GxOXW0XWwAAhI1o?format=jpg&name=900x900
Long COVID Research.
ARPA-H is urged to invest in Long COVID research to ensure its
high-risk, high-reward research is focused on drug trials, development
of biomarkers, and research that includes Long COVID associated
conditions, such as dysautonomia, postural orthostatic tachycardia
syndrome [POTS], and myalgic encephalomyelitis/chronic fatigue syndrome
[ME/CFS]. The Committee urges ARPA-H to coordinate with NIH on these
efforts to augment NIH's Long COVID research portfolio. ARPA-H is also
urged to prioritize the support of R&D programs and projects that can
enable clinical trials evaluating therapies which target key symptoms
and symptom complexes associated with Long COVID including widespread
pain, fatigue, non-restorative sleep, brain fog, dizziness,
post-exertional malaise [PEM], POTS and loss of taste and smell.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
https://pbs.twimg.com/media/GxOXW0SWcAEivlJ?format=jpg&name=900x900
Long COVID Treatments.
The Committee remains concerned about the economic and overall health
impact that Long COVID inflicts on the Nation. It is currently estimated
that between 6 percent and 19 percent of those infected with SARS—CoV-2
go on to develop Long COVID, resulting in up to 20 million Americans
suffering from this set of debilitating chronic symptoms. Long COVID is
characterized by a wide range of symptoms including severe fatigue, non
restorative sleep, cognitive dysfunction, and widespread pain. Further,
it resembles other post-acute infection syndromes [PAISs], such as
fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome
[ME/CFS] and related conditions, known as chronic overlapping pain
conditions [COPCs] or nociplastic syndromes. While the Committee is
pleased that NIH’s HEAL and RECOVER initiatives plan to target some
specific symptoms of Long COVID, the Committee is concerned that NIH has
not expanded the evaluation of treatments to address many common
symptoms associated with Long COVID either individually or that present
as syndromes which are combinations of symptoms. Furthermore, NIH's
research program has defined Long COVID narrowly, excluding many of the
common symptoms plaguing Long COVID sufferers. In June 2024, NASEM
released the 2024 NASEM Long COVID Definition, which encompasses
extensive lists of the symptoms and diagnosable conditions that current
science attributes to Long COVID. The Committee urges NIH to rebalance
its research program to prioritize clinical trials in pursuit of
effective treat-
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
https://x.com/njfatigue/status/1951069487115149448/photo/3
https://pbs.twimg.com/media/GxOXW0RXgAIq87K?format=jpg&name=900x900
ments and to use the NASEM Long COVID definition to guide its choice of
symptoms and conditions to be address by the candidate treatments. Such
trials should target key symptoms and symptom complexes associated with
Long COVID including widespread pain, fatigue, non-restorative sleep,
brain fog, dizziness, post-exertional malaise [PEM], postural
orthostatic tachycardia syndrome [POTS] and loss of taste and smell.
Further, the Committee urges NIH to prioritize the support of clinical
trials evaluating therapies for Long COVID including therapies that have
demonstrated efficacy in treating COPCs or nociplastic syndromes that
overlap with Long COVID.